Trial Profile

A Phase I, Open-Label, Two-Arm Study of MP-424 [telaprevir] in Combination With Peginterferon Alfa 2b and Ribavirin in Patients With Genotype 1b Hepatitis C

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 10 Apr 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Telaprevir (Primary) ; Peginterferon alfa-2b; Ribavirin
Indications Hepatitis C
Focus Pharmacokinetics
Sponsors Mitsubishi Tanabe Pharma Corporation

Most Recent Events

17 Jan 2013 Actual initiation date changed from Jan 2008 to Apr 2008 as reported by ClinicalTrials.gov.
04 Sep 2009 Actual end date (Mar 2009) added as reported by ClinicalTrials.gov.
04 Sep 2009 Status changed from recruiting to completed as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com